Indications: Aducanumab is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease.

MOA:  Aducanumab is a human, immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease. Aducanumab reduces amyloid beta plaques,

Dosing:  After an initial titration, the recommended dosage of Aducanumab is 10 mg/kg; Aducanumab is administered as an intravenous (IV) infusion over approximately one hour every four weeks.

Precaution: Amyloid-related imaging abnormalities (ARIA )are abnormal differences seen in neuroimaging of Alzheimer's Disease patients, associated with amyloid-modifying therapies, particularly human monoclonal antibodies such as aducanumab. There are two types of ARIA - ARIA-E (edema) and ARIA-H (hemorrhage).